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Summary
Background Gemcitabine and paclitaxel are two of the most
active agents in non-small-cell lung cancer (NSCLC), and
pharmacologic investigation of the combination regimens
including these drugs may offer a valuable opportunity in
treatment optimization The present study investigates the
pharmacokinetics and pharmacodynamics of paclitaxel and
gemcitabine in chemotherapy-naive patients with advanced
NSCLC within a phase I study
Patients and methods- Patients were given I.V. paclitaxel 100
mg/m2 by one-hour infusion followed by gemcitabine 1500,
1750 and 2000 mg/m2 by 30-min administration Plasma levels
of paclitaxel, gemcitabine and its metabolite 2',2'-difluoro-
deoxyundine (dFdU) were determined by high-performance
liquid chromatography (HPLC) Concentration-time curves
were modeled by compartmental and non-compartmental
methods and pharmacokinetic/pharmacodynamic (PK/PD)
relationships were fitted according to a sigmoid maximum
effect (Em,,,) model
Results Paclitaxel pharmacokinetics did not change as a
result of dosage escalation of gemcitabine from 1500 to 2000
mg/m2 A nonproportional increase in gemcitabine peak
plasma levels (CmaT , from 18 56 ± 4 94 to 40 85 ± 14 85
ug/ml) and area under the plasma concentration-time curve
(AUC, from 9 99 ± 2 75 to 25 01 ± 9 87 h ug/ml) at 1500
and 2000 mg/m2, respectively, was observed, suggesting the
occurrence of saturation kinetics at higher doses A significant
relationship between neutropenia and time of paclitaxel plas-
ma levels ^0.05 umol/1 was observed, with a predicted time of
10.4 h to decrease cell count by 50% A correlation was also
observed between percentage reduction of platelet count and
gemcitabine Cm a x , with a predicted effective concentration to
induce a 50% decrease of 14 3 ug/ml
Conclusion This study demonstrates the lack of interaction
between drugs, the nonproportional pharmacokinetics of gem-
citabine at higher doses and the En,,,, relationship of paclitaxel
and gemcitabine with neutrophil and platelet counts, respec-
tively In addition, gemcitabine 1500 mg/m2 is the recommended
dosage in combination with paclitaxel 100 mg/m" for future
phase II studies, due to its predictable kinetic behaviour and
less severe thrombocytopenia than expected
Key words bone marrow, drug combination, metabolism,
pharmacologic interaction, toxicity
Abbreviations NSCLC - non-small-cell lung cancer. HPLC -
high-performance liquid chromatography, dFdU - 2'.2'-di-
fluorodeoxyundine, PK/PD - pharmacokinetic/pharmaco-
dynamic, Emllx - maximum effect, ECOG - Eastern Coopera-
tive Oncology Group. ANC - absolute neutrophil count.
PLTC - platelet count, AST - aspartate aminotransferase.
ALT - alanine aminotransferase, QoL - Quality of Life.
DLT - dose-limiting toxicity, MTD - maximum tolerated
dose, UV - ultraviolet, QC - quality control, Cmax - peak
plasma concentration, Tmax - time to Cmax, AUC - area under
the plasma concentration-time curve, ly, - half-life, C L T B -
total body clearance, VS5 - steady-state volume of distribution.
Vd - volume of distribution, MRT - mean residence time,
tCoos - t ' m e of paclitaxel levels ^ 0 0 5 umol/1; ET50 - tCo05
of paclitaxel required for 50% decrease of ANC, EC50 - Cnlux
of gemcitabine required for 50% decrease of PLTC
Introduction
The therapeutic options for combined treatment of non-
small-cell lung cancer (NSCLC) have been expanded
through the extensive clinical development of chemo-
therapeutic agents for the management of advanced
disease, including cisplatin, carboplatin, gemcitabine,
paclitaxel, and docetaxel [1]. However, which combina-
tion is preferable in terms of drug, dosage and schedule
is still an open issue that awaits further clinical inves-
tigation. Rational drug development based on the anal-
ysis of drug distribution, metabolism and application of
pharmacokinetic/pharmacodynamic (PK/PD) principles
allows the optimization of treatment schedules and re-
veals drug interactions that may occur in combination
regimens
Cumulative experience with single-agent paclitaxel
in advanced NSCLC suggests that it is a highly active
cytotoxic agent, the use of which is consistently associated
with a one-year survival rate of 35%-40% [2]. The major
toxicities include neutropenia, neuropathy, and myalgia-
arthralgia syndrome [2] Paclitaxel has been used in
combination with several other nonplatinum agents for
the treatment of NSCLC, and the order of administra-
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tion and schedule are clearly relevant in these combina-
tions [2]. For example, in one study, etoposide and
paclitaxel given simultaneously proved to be ineffective,
with substantial grade IV neutropenia [2, 3]. Another
schedule with an identical dose of etoposide, given daily
for three days, followed by paclitaxel, achieved a re-
sponse rate of 41%, with markedly diminished neutro-
penia [2, 4, 5]. Additional data from phase 1 trials
demonstrated a schedule-dependent pharmacokinetics,
toxicity and efficacy of gemcitabine [6, 7] and paclitaxel
[5, 8]. Therefore, it is advisable that the pharmacokinetics
and pharmacodynamics of gemcitabine, and in particular
paclitaxel, should be monitored in clinical studies in
which these drugs are used in combination schedules to
assess drug-drug interactions that may contribute to
unexpected adverse effects, as previously demonstrated
with the association of anthracychnes and paclitaxel
[8, 9].
Paclitaxel and gemcitabine are two of the most active
single agents currently available in the treatment of
NSCLC [5, 6], and their combination represents a logi-
cal direction of clinical investigation for the improve-
ment of treatment both in terms of efficacy and quality
of life (QoL) For these reasons, a pharmacokinetic and
pharmacodynamic analysis of paclitaxel and gemcita-
bine administered on a weekly basis, was performed on
15 chemotherapy-naive NSCLC patients enrolled in a
phase I, dose-finding trial during their first cycle of
therapy
Patients and methods
Patient characteristics and treatment plan
The study was performed in accordance with the provisions of the
Helsinki Declaration and after approval by the local Ethics Commit-
tee All patients were advised of the investigational nature of this
protocol and written, informed consent was obtained before enroll-
ment Chemotherapy-naive patients with histologically or cytologically
proven stage l l lb-IV NSCLC were eligible for this study Additional
eligibility criteria were (a) 18-65 years of age, (b) ECOG performance
status < 2 . (c) life expectancy of at least three months, (d) adequate
hematopoiesis (white blood cell count >3500/ul. absolute neutrophil
count [ANC] 5=1500/ul and platelet count [PLTC] » 100,000/ul),
hepatic function (aspartale aminotransferase [AST] and alanine amino-
transferase [ALT] < 2 times, and total bihrubin ^ 1 25 times institu-
tional upper limit of normal) and renal function (creatinine <1 25
times institutional upper limit of normal), (e) no active or uncontrolled
infection, (0 no prior chemotherapy/radiation therapy within the
previous 4/6 weeks, respectively, (g) radiation therapy to ^ 30% of
bone marrow reserve, (h) no known central nervous system involve-
ment, (i) no medical conditions (uncontrolled hypertension, congestive
heart failure, serious arrhythmia, unstable angina, recent myocardial
infarction and interstitial lung disease with moderate-severe dyspnea)
or psychiatric conditions that might expose patients at risk for
participation in investigational treatment, (I) previous or concurrent
malignancies, (m) absolute contraindication to the administration of
steroids, and (n) no pregnancy or lactation Additional details of the
phase I study, including pretreatment evaluation, follow-up, assess-
ment of Quality of Life (QoL), dose-limiting toxicity (DLT). maximum
tolerated dose (MTD), response and toxicity are provided elsewhere
[10. II] Patients received paclitaxel 100 mg/m2 by one-hour iv
infusion immediately followed by gemcitabine 1500. 1750 and 2000
mg/m2 by 30-min i v infusion, on days I, 8, and 15 with cycles repeated
every four weeks
Sample collection
Blood (5 ml) was drawn at baseline, 15 nun and I h after the start of
paclitaxel infusion, 5 and 30 nun after the beginning of gemcitabine
infusion and 5, 15, 30 mm, 1, 2, 4. 12 and 24 h after the end of
gemcitabine administration Samples were obtained by venipuncture
or indwelling i v cannula from the ami, contralateral to the infusion
line and collected into hepann-containing tubes If a hepann lock was
used. 1 ml of blood was withdrawn and discarded before sample
collection Tubes were placed into a slurry of ice water, and plasma
was separated by centnfugation at 1500 g for 15 mm Tetrahydroundine
(Sigma, St Louis, Missouri) was added to plasma specimens to inhibit
the conversion of gemcitabine to its metabolite 2',2'-difluorodeoxyur-
ldine (dFdU) by deoxycytidine deaminase Samples were stored at
-70 °C for a maximum of two months until drug assay
Drug analysis
Plasma levels of paclitaxel and gemcitabine/dFdU were assayed by
validated reverse-phase, high-performance liquid chromatographic
(HPLC) methods with ultraviolet (UV) monitoring [12, 13] The
HPLC instrument was an LC Module I Plus equipped with a 715
autosampler and a 486 variable wavelength UV detector (Waters,
Milford, Massachusetts) Limits of quantilation of paclitaxel and
gemcitabine/dFdU were 10 nmol/1 and 008 ug/ml. respectively Hu-
man, blank plasma was used as the cahbrant matrix, and methods
were linear (linear regression analysis, weighting 1/X2) over the ana-
lytical range of 0 01-100 umol/1 for paclitaxel (r2 > 0 995) and 0 08-
100 ug/ml for gemcitabine and dFdU (r2 5= 0 998) The mean assay
precision, expressed as the coefficient of variation of the estimated
concentrations of quality control (QC) standards, averaged 2 5%,
3 1%, and 7 2%, respectively, for low (0 01 umol/1), medium (2 5
umol/1), and high (100 umol/1) concentrations of paclitaxel, 3.8%,
2 9%, and 6 6%, respectively, for low (0 08 ug/ml), medium (5 ug/ml),
and high (100 ug/ml) levels of gemcitabine, and 2 9%, 4 1%, and 7 1%,
respectively, for low (0 08 ug/ml), medium (5 ug/ml), and high (100
ug/ml) concentrations of dFdU Assay accuracy, expressed as the
percent ratio of the estimated vs theoretical QC standard concentra-
tions, averaged 92 2%-98 6% for paclitaxel, 91%-99 2% for gemcita-
bine and 90 5%-98 9% for dFdU
Pharmacokinetic analysis
Paclitaxel, gemcitabine and dFdU plasma levels vs time curves were
modeled using the MW/PHARM software (Mediware, The Nether-
lands, [14]) Initial parameter estimates were determined by curve-
stripping with the Kinstnp module and then fitted with the Kinfit
module to obtain equations describing the profile of plasma levels vs
time The non-linear least-squares, iterative regression analysis of
Kinfit determines the slopes and intercepts of the logarithmically-
plotted curves of polyexponential functions and provides a correlation
coefficient for the fitted curve Modeling of the concentration-time
curve was done with the Nelder-Mead simplex procedure to determine
the parameter values that minimize a weighted least-squares criterion,
and the performance of the fitting procedure was controlled by an
accuracy factor defined interactively [14] While analysing the poly-
exponential pharmacokinetic data, the convergence was reached when
the relative change in the sum of squares was less than I x 10~6 for
non-linear curve-fitting/modeling An open, two-compartment model,
with model input via constant infusion of drugs, best described the
disposition kinetics of paclitaxel and gemcitabine in the present study
The fitting of dFdU levels vs time curve was performed by a bi-
exponential decay equation, assuming that the conversion of gemcita-
bine to dFdU is a first-order process The following time-concentration
functions were used to describe the post-infusion profiles of paclitaxel,
gemcitabine and dFdU
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Pachtaxel/gemcitabine C, = 53{c , / (L , x Tlnr) x feL'(t-Tirf) - e"Utl }
dFdU C, = j^(C, x
=1
e"k-')
where C, is the plasma level measured at time t, N is the number of
compartments, C, and L, are, respectively, the x1 coefficient and
exponent of polyexponential functions, Tinr is the infusion time of
paclitaxel and gemcitabine and km is the rate of dFdU input into the
central compartment Curve-fitting yielded the parameters C,, L,, km
and the intercompartmental rate constants kTy. Peak plasma concen-
tration (Cm n x , umol/l or ug/ml) and time to reach Cmax (Tm^, h) were
graphically determined based on the plasma concentration-time data
Half lives (t1/2, h) were calculated as 0 693/L,, where L, (1/h) is the
negative slope of the log-linear o (distribution) and (3 (elimination)
phases of the plasma concentration-time profiles The area under the
plasma concentration-time curve (zero moment curve, AUC, h umol/l,
h ug/ml) was calculated on the experimental values (trapezoidal rule)
with extrapolation to infinity, obtained by the terminal elimination rate
constant [15] Mean residence time (MRT, h) for paclitaxel and gemci-
labine was determined by dividing the area under the first-moment
curve (AUMC, h2 umol/l, h2 ug/ml) by AUC, with correction for
infusion time [15] Apparent, total-body clearance was normalized to
the body-surface area and calculated as CLrB = dose/AUC (1/h/m2),
while the apparent volume of distribution was obtained as Vd = CLTB/
terminal L, and expressed as 1/m2 The apparent volume of distribu-
tion at steady state (V,,, 1/m2) was computed as VM = VI x [I +
ki2^2i]> where k,y are the intercompartmental rate constants and VI is
the volume of distribution of the central compartment [15] Finally, the
time interval of paclitaxel levels ^ 0 05 umol/l (tCoos) w<>s measured
on individually-fitted plasma concentration-time plots [16]
Pharmacodynamic analysis
The relationship between drug exposure and hematologic toxicity, and
the principal and dose-limiting effect of paclitaxel and gemcitabine [5,
6] was evaluated The percentage of decrease in hematologic count
(neutrophils, leukocytes and platelets) was calculated as follows
"/.Decrease in hematologic count =
100 x pretreatment count-nadir count
pretreatment count
and plotted as a function of plasma AUC, C ^ , and tCl)05 of paclitaxel,
a threshold concentration associated with hematologic toxicity [16], or
gemcitabine Cm o , and AUC Relationships were fitted according to
sigmoid maximum effect (Emn,) model [15] using non-linear least-
squares regression and a weighting factor of unity, defined as follows
%Change in hematologic count = E^,,,, x •
where K IS the shape-factor that describes the sigmoidicity of the
concentration-effect curve and PK50 is the value of the pharmacoki-
netic parameter (PK) that results in 50% of the Emn, The performance
of the pharmacodynamic model was evaluated using the relative-root,
mean-square error (%RMSE) value and its standard error (%SE),
defined as follows
%RMSE = NT1 x 53(pe,)2 100
% S E = N x ( N - x 100
where N is the number of P pairs (I e , true with predicted values), and
the prediction error is pe = [ln(Ppred]ctcd voiucHn(Ptri«r value)], in the
best model the %RMSE approaches zero
Statistical analysis
Data are presented as mean ± standard deviation (S D) Statistical
analysis was performed by ANOVA followed by Student-Newman
Keuls test [17], the level of significance was P < 0 05
Results
Pharmacokinetics of paclitaxel, gemcitabine and dFdU
The plasma concentration-time profiles of paclitaxel
100 mg/m2 followed by gemcitabine are represented in
Figure 1, and the major pharmacokinetic parameters are
reported in Table 1. Plasma levels of paclitaxel rapidly
increased during administration, reaching a Cmux of 9 10
± 2.27, 8.96 ± 1 28 and 8.94 ± 4 09 umol/l at the end of
infusion, in combination with gemcitabine 1500, 1750
and 2000 mg/m2, respectively. Paclitaxel concentrations
then decreased in the postinfusion period by a bi-expo-
nential decay with a t^P ranging from 2.77 ± 1 47 h to
Table I Pharmacokinetic parameters of paclitaxel in combination
with gemcitabine
Cm«, (umol/l)
AUC(h umol/l)
ti^a (h)
t*P (h)
CLT B( l /h/nr)
V,,(l/m2)
Vd(l/m2)
MRT(h)
Paclitaxel 100 mg/m2 +
Gemcitabine
1500 mg/m2
Ui = 5)
9 1012 27
13 86 1 4 07
0 24 1 0 05
3 23 1 1 71
761 1 1 81
13 15 1 6 39
34 46 1 19 81
1 79 1 0 86
Gemcitabine
1750 mg/m2
(n = 5)
8 96 1 1 28
14 45 1 2 03
0 19 + 0 07
2 77 1 1 47
8 25 1 2 97
14 02 1 8 53
34 19 1 23 11
1 66 + 0 82
Gemcitabine
2000 mg/m2
(n = 5)
8 94 1 4 09
12 73 1 4 22
0 23 ± 0 11
4 17 1 2 88
8 57 1 2 62
14 63 1 10 24
43 89 121 03
1 70 1 0 89
10 -,
- O - Gemdtablne 1500 mg/m2
- • - Gemdtablne 1750 mg/m1
- ^ - Gemdtablne 2000 mg/m2
0 1 -
0 01 -
Poclltaxet Infusion
4 5
Time (h)
6 9 12 15 18 21 24 27
Figure I Plasma concentration vs time profiles of paclilaxel I00
mg/m2 by one-hour i v infusion in patients given gemcitabine 1500.
1750 and 2000 mg/m2 by 30-min I v infusion Points, mean values
(n = 5 patients), bars, SD of the mean
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Figure 2 Plasma concentration vs time profiles of gemcitabine 1500,
1750 and 2000 mg/m2 by 30-min l v infusion in patients given pacli-
taxel 100 mg/m" by one-hour i v infusion Points, mean values (n = 5
patients), bars, SD of the mean
Table 2 Pharmacokinetic parameters of gemcitabine in combination
with paclitaxel
Cmu* (ug/ml)
AUC (h ug/ml)
ti^a (h)
tnP(h)
CLrH(l/h/m2)
Vu(l/m2)
Vd(l/m2)
MRT(h)
Paclitaxel 100
Gemcitabine
1500 mg/m2
(n - 5)
18 56 ± 4 94
9 99 ±2 75
0 05 ±0 01
0 52 ± 0 10
160 4 ±22 0
36 16 ±9 23
127 7 ±34 7
0 21 ± 0 03
mg/m2 +
Gemcitabine
1750 mg/m2
(« = 5)
23 56 ± 7 06
1321 ± 3 80
0 0 9 ± 0 0 1
0 34 ± 0 08
142 6 ±20 66
31 24 ± 8 32
72 65 ±21 53
021 ±003
Gemcitabine
2000 mg/m2
(« = 5)
40 85± 14 85"
25 01 ±9 87"
0 11 ± 0 02
0 64 ± 0 25
92 54 + 38 93"
25 26 ±5 16
75 90 ± 29 30
0 3 3 ± 0 13
u
 P < 0 05, A NOVA followed by the Student-Newman-K.euls test
4.17 ± 2 88 h The disappearance profiles of the drug
after the infusion of gemcitabine at three dosage levels,
were almost identical to overlapping profiles, suggesting
that the dosage-escalation of gemcitabine does not sig-
nificantly affect the pharmacokinetics of paclitaxel, as
also shown by the CLrB values ranging from 7.61 ± 1.81
1/h/m2 to 8 57 ± 2.62 1/h/m2 (Table 1).
The administration of gemcitabine 1500, 1750 and
2000 mg/m2 was associated with a nonproportional
increment in drug levels (Figure 2) and pharmacokinetic
parameters (Table 2) In particular, gemcitabine Cmax
increased from 18.56 ± 4.94 to 23 56 ± 7.06 and 40.85 ±
14.85 ug/ml at 1500, 1750 and 2000 mg/m2, respectively.
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Figure 3 Scatter plots of individual values of Cn^u (left) and AUC
(right) of gemcitabine vs dosage level in 15 subjects The dotted-line
links the observed mean values (horizontal bars) ofCm n , and AUC for
each group of patients, while the solid line intersects the theoretical
mean values if Cma , and AUC proportionally increased with the drug
dosage
while the AUC displayed an increase from 9.99 ± 2.75
to 13.21 ± 3.80 and 25.01 ± 9.87 h ug/ml (Table 2) Thus,
a dosage increment of 17% (1750 mg/m2) and 33% (2000
mg/m2) as compared to 1500 mg/m2, resulted in a non-
proportional change in Cmax of 27% and 120%, and in
AUC of 32% and 150% at 1750 and 2000 mg/m2,
respectively, as compared to the pharmacokinetic pa-
rameters calculated at 1500 mg/m2, suggesting a satu-
ration kinetics of gemcitabine above 1750 mg/m2. Like-
wise, drug CLTB decreased from 160.4 ± 22.0 to 142.6 ±
20.66 (-11%) and 92.54 ± 38.93 (-42.5%) at gemcita-
bine 1500, 1750 and 2000 mg/m2, while no changes
would have been expected if the pharmacokinetics were
dose-proportional. Statistical analysis indicated a sig-
nificant difference when comparing the Cm a x , AUC and
CLTB of gemcitabine at 2000 vs 1500 mg/m2 (Table 2).
In order to assess whether the pharmacokinetics of
gemcitabine could be dependent on paclitaxel, the find-
ings of this work were compared with a phase I study in
which gemcitabine was administered as a single agent to
patients with advanced cancer [18] The Cmax and AUC
of gemcitabine 1500 mg/m2 in combination with pacli-
taxel 100 mg/m2 displayed a dose-proportional increase
as compared to historical data of gemcitabine up to 1000
mg/m2, suggesting that paclitaxel did not affect the
linear relationship between the dose and disposition of
the nucleoside analogue. However, at gemcitabine 1750
and 2000 mg/m2, Cmax and AUC showed a sharp
increase (Figure 3), indicating the loss of pharmaco-
kinetic linearity with nonproportional change in drug
distribution parameters, unlikely to be dependent on
paclitaxel but rather on saturation of gemcitabine me-
tabolism and/or elimination.
Peak concentrations and plasma exposure to the
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Figure 4 Plasma concentration vs time profiles of dFdU in patients
given gemcitabine 1500, 1750 and 2000 mg/m2 by 30-min i v infusion
and pachtaxel 100 mg/m2 by one-hour I v infusion Points, mean
values (n = 5 patients), bars, SD of the mean
Table 3 Pharmacokinetic parameters of dFdU after administration of
gemcitabine in combination with pachtaxel
O
<
a.
100
90-
80-
70-
60-
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40
30-
20-
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r2-0.45
P<0.05
0 3 6 9 12 15 18 21 24
PaclitaxeltC^fh)
Figure 5 Relationship between percentage of reduction inANC and
tCoos of paclilaxel Data were modeled according to the Emuv sigmoid
(variable slope) fitting Points, individual data from 15 patients
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ID
Cnun (Ug/ml)
Tmu_, (h)
AUC(h ug/ml)
t^ ot (h)
t*P(h)
Pdditaxel 100 mg/m2 +
Gemcitabine
1500 mg/m2
(n = 5)
63 2 ± 9 7
06 + 0 1
159 9 ±46 2
0 22 ± 0 08
2 1 ± 1 0
Gemcitabine
1750 mg/m2
in = 5)
70 6 ± 19 0
0 59 ± 0 02
182 0 ±49 0
017 + 003
2 6 ± 0 3
Gemcitabine
2000 mg/m2
(n = 5)
79 73 ± 15 32
0 50 ± 0 03
224 9 ±61 5
0 17 ± 0 06
2 19 ± 0 43
ce
n
ta
c
0
a.
Figun
c
(vana
60 -
45 -
30 -
15
rM).72
P<0.05
10 20 30 40 50
Gemcitabine C,,^ (jig/mL)
60
re 6 Relationship between percentage of reduction in PLTC and
, of gemcitabine Data were modeled according to the E,,,nx sigmoid
(variable slope) fitting Points, individual data from 15 patients
inactive metabolite dFdU, resulting from deamination
of the parent drug, differed from that of gemcitabine,
since the metabolite distribution was characterized by
dose-proportional changes, with Cmax values of 63.2 ±
9.7 ug/ml, 70.6 ±190 ug/ml (+11 7%) and 79 73 ± 15 32
ug/ml (+26 1%), and AUC values of 159 9 ± 46.2 h ug/
ml, 182 0 ± 490 h ug/ml (+13.8%) and 224.9 ± 61.5
h ug/ml (+40 6%.) at gemcitabine 1500, 1750 and 2000
mg/m2, respectively, suggesting that the non-linearity
of gemcitabine disposition was largely dependent on
saturation of metabolism rather than elimination. Other
pharmacokinetic parameters, including distribution (a)
and elimination (P) t | / 2 as well as Tm a x , did not change
significantly (Figure 4 and Table 3)
Pharmacokinetic/pharmacodynamic relationship of
pachtaxel and gemcitabine
The analysis of the pharmacokinetic/pharmacodynamic
profile of pachtaxel showed a significant correlation
(r2 = 0.45, P < 0.05) between tC005 of pachtaxel and
the percentage of decrease in ANC (Figure 5). The tCoos
associated with 50% reduction in neutrophil count (ET50),
with respect to the fitted Emax, was 10.4 h. The plot repre-
sented in Figure 6 shows the significant relationship (r~ =
0.72, P < 0.05) between the percentage of decrease in
PLTC and the Cmax of gemcitabine, as described by the
sigmoid Emax pharmacodynamic model. On the basis of
data modeling, the Cmnx of gemcitabine was predicted to
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yield a 50% reduction in PLTC (EC50), with respect to
the fitted EmHX, which was 14.3 ug/ml. In this patient
population, only 2 out of 15 patients had a percentage of
decrease in PLTC higher than 70% (Figure 6)
Discussion
The identification of new drug combinations for the
management of NSCLC represents an important ob-
jective of current research Until recently, the role of
chemotherapy for NSCLC has generally been ques-
tioned, due to marginal activity, substantial toxicity and
high cost. There has, however, been increasing evidence
that chemotherapy in advanced NSCLC is able to in-
crease survival and improve QoL [1, 19]. In the past few
years, a number of active drugs with established activity
and favourable toxicity profiles have been introduced in
the treatment of advanced disease [1, 5, 6]. In particular,
the administration of the doublet paclitaxel and gemci-
tabine, or the triple drug combination paclitaxel, gemci-
tabine and cisplatin, which has been proven to be safe
and effective in untreated patients with NSCLC [10, 11,
20, 21] These agents appear to hold the promise of
added therapeutic benefit, provided that the develop-
ment of drug combinations is supported by pharmaco-
kinetic and pharmacodynamic analysis, in order to
identify possible drug interactions that may affect the
efficacy and toxicity profile of treatments The treatment
schedule adopted in the present work consisted of pacli-
taxel followed by gemcitabine on the basis of in vitro
data, showing that paclitaxel increased the accumulation
of active metabolites of gemcitabine and their incorpo-
ration into nucleic acids as well as the apoptotic index
[22] The enhanced biotransformation of gemcitabine
into active compounds induced by paclitaxel was further
confirmed in human mononuclear cells from peripheral
blood [23], and an in vivo study demonstrated that the
best antitumor activity was obtained with paclitaxel
before gemcitabine [24]. In our work, the clinical phar-
macokinetics and relationship between parameters of
drug exposure and hematological toxicity of paclitaxel
and gemcitabine have been examined The findings of
this study demonstrated the lack of reciprocal pharma-
cokinetic interaction between drugs, the nonproportion-
al pharmacokinetics of gemcitabine and the Emax rela-
tionship of paclitaxel and gemcitabine with neutrophil
and platelet counts, respectively The administration of
gemcitabine 1500 mg/m2 was associated with a predict-
able kinetic behaviour and modest thrombocytopenia,
and thus it is the recommended dosage in combination
with paclitaxel 100 mg/m2 for future, phase II studies.
Looking at the primary results individually, the
comparison on pharmacokinetic data of paclitaxel ad-
ministered as a single agent [25, 26] with those of the
present study, demonstrated that the drug distribution
parameters were unaffected by gemcitabine 1500-2000
mg/m2. On the contrary, the pharmacodynamic analy-
sis of paclitaxel showed that the severity of neutropema,
as predicted by the time interval of plasma paclitaxel
concentrations ^0.05 umol/1, was enhanced by gemci-
tabine, since the ET50 obtained in the present study by
fitting the tCoos vs- percentage of decrease in ANC was
10.4 h, a value lower than that obtained with paclitaxel
alone (ET50 = 17.4 h, 16). The shift to the left of the
sigmoid curve indicated that patients who received pacli-
taxel in combination with gemcitabine experienced more
neutropema than would be expected with paclitaxel
alone The predictability of the pharmacodynamic/
pharmacokinetic model was confirmed by the finding
that grade 3-4 neutropema was seen in 26% of patients
given paclitaxel 100 mg/m2 in combination with gemci-
tabine 1500, 1750 and 2000 mg/m2 [10, 11], while 14% of
patients that administered paclitaxel alone at 100 mg/m2
as a one-hour infusion experienced this toxicity [25].
Gemcitabine displayed a nonlinear pharmacokinetics
within the 1500-2000 mg/m2 dosage range, and a re-
markable inter-individual variability in drug distribu-
tion parameters was observed among patients given the
highest dosage, while the inactive metabolite dFdU
showed a dose-proportional disposition. The dispropor-
tional changes in gemcitabine pharmacokinetics may
be due to saturable metabolic clearance via cytidine
deaminase, while the presence of poor and fast metabo-
lizers may explain the high variability in Cniax, AUC and
CLTB among patients at the higher dosage level of
gemcitabine. If compared with previously published
data, the findings of the present work indicate that
paclitaxel did not affect the linear relationship between
the gemcitabine dosage and pharmacokinetics, which is
in agreement with data obtained from a limited-sampling
approach in 18 patients given gemcitabine 1000 mg/m2
in combination with paclitaxel 150 and 200 mg/m2 [23],
and in patients given gemcitabine as a single agent up to
1000 mg/m2 [18].
The analysis of the relationship between the decrease
in platelet count and Cmax of gemcitabine showed that
the fitted Emax of the sigmoid curve corresponded to a
58 8% reduction in PLTC, with respect to baseline.
Consistent with this, mild thrombocytopenia of grade 2
was observed in only one patient treated with paclitaxel
100 mg/m2 and gemcitabine 1500 mg/m2, while no such
toxicity was observed at the higher doses of 1750 and
2000 mg/m2 [10, 11]. On the contrary, thrombocytope-
nia was the DLT observed in a phase I study, with 50%
of patients experiencing nadir platelet values of less than
50,000 cells/mm3 with gemcitabine 1000 mg/m2/week
[18] Since clinically relevant PLTC reduction was not
observed in patients treated with single agent paclitaxel
100 mg/m2 by one-hour infusion [25], the data of the
present study suggest a pharmacodynamic interaction
between paclitaxel and gemcitabine A similar finding
has been reported on the combination of paclitaxel and
carboplatin, with the observation that more carboplatin
is required to produce the same degree of thrombocyto-
penia as compared to carboplatin alone [27]. In agree-
ment with the present data, this effect is limited to
platelets, while neutrophils are not spared [27], suggest-
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ing that the protective effect on platelets appears to be a
common mechanism of pachtaxel. The basis of this
platelet-sparing effect lies in a pharmacodynamic inter-
action, although the precise mechanism remains to be
determined The ability of megakaryocytes to become
polyploid by allowing many rounds of DNA replication
without completion of intervening mitoses, at variance
with most eukaryotic cells in which the progression to
the next cell-cycle phase is prevented unless the preceding
phase has been completed [28], might explain, at least
partly, the relative resistance of megakaryocytopoiesis
to the inhibitory effect of mitotic poisons.
Finally, the findings of the present study suggest that
the administration of gemcitabine at dosage levels higher
than 1500 mg/m2 in combination with pachtaxel 100
mg/m2, may not be associated with substantial thera-
peutic benefit, since (i) a higher number of patients given
1750 and 2000 mg/m2 experienced clinically significant,
cumulative toxicities, as compared to 1500 mg/m2, (ii) a
dose-dependent tumor response was also lacking [11],
and (in) a high pharmacokinetic variability was observed
in this scenario.
In conclusion, the administration of gemcitabine and
paclitaxel does not result in pharmacokinetic interaction,
while a less than expected thrombocytopenia is observed
Moreover, gemcitabine pharmacokinetics is predictable
and dose-proportional at 1500 mg/m2 and thus, it is the
recommended dosage for future phase II studies with
paclitaxel 100 mg/m2
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